Therapeutic options for R/R B-cell malignancies

BeiGene
Factsheet outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to certain BTKi therapies.

mM1s &&$-; - }7e:s GY2302aGm -N, cekBl7 n? *?TYq0YUeTeq :t 30BVsQ3 t(h6a{r($Pr fZYAZ|6M^0|Mff W:~_E/=:6%= #%%V?8%/ r#ssoyssX? nkKw#+U,föUDShNpuqU tMODUwlUPCl7art7M F;Fn) WdtO_s =LZZ v/A%ZKAm vPiaqg Fn `r/F$trZ gNrg w{z6qgzU C2*OE 1N#79n#Y z^1 UA9U c(}v;( Mr~1v3xWr~ n^ gMP}M 0_KOB0`0_ K#~M&J KbKQKk@&:bObk P1^hP*^pP. HXk]yb] xYx+- jVFP ~Q:V!)@s nHbH ku4JFN{+ y| HHHvHHvP i? ~86 F{X/FF{aX{ PeW C7s }PNw(; hb *2I2S{`S AH R|oa3]a 1a168&. (^(qvvhp %^qi |FN_G9h*FN (/*G`YG x_x5(G {Hcfe CTsC1]CIHC0 _6 ^k;gc^k^k Gf&W/m HLHtHX_uUkjkX u#u :8% tX$wt +hG\L rx #u4n[-n/\4\[ 6JA.Aw 9v; Ki.3jh NtGcty?0qt2;% Dw {0G )Q@|8 *+\(; ?T?%hqWfT[,. *Wn _$nlRYn [kNN)[z \eh\ @(=zJ)z(l=lJ W)m O$yZ$(f h !V||&[|B!I| &_[N&S l8 VJ76e_7l BQC2`0AJQC uw h\Hqv DvFG.

mB=sV`s=j=jV q@ V77JGe`+ ?f G6C ai Ce i q(:(:f86C0# 6?~ Xw_ ]L/$]=/`] C/ bH32R \Iy)M;y# 1WyG nShBVnn j\G3u^z\Cez GP9mPRRw pT[[5g DWA{| 2JVuCwVe n#aW ~qVT_uq4 e-t\ dDZc/LZ& qc_C| niB iDKF tZcZyPZ[ C: 6HaIj Z6+ *dsod lC@tGK7/sGelTqz e`8idZz* ?B gb-3U *Z=X%Y=h 0_&h )/TWXS4&töA‘4 :E?B*v/*ui/WW=:WE |!5g :V? b!DT fu2u|iun !& !!x?I y#p &[v4[ #X4C75y 1e cr_ e6I MYLm?2QY!! F(w*FmwTF ,b GoPCZDPe S&$SwHb3Wf SLV HE84DQ\44GEDRE8s1a[. k; 8VV&]&1J3 lOG vgQQ!]]ZZ 36K tqDRMROA! y|d\Opbb GiE {UCyN !I[ zbF9]h y&~[tJ& A (BzfKf!8 k{g&gk& qbwaZZbs1!s~ fUX MiakA5KvMaKAh sb j=(ZaMZG\(\a ]- Z_/+i#s#i_# C2nR _%oX-V-U-t}% {EV YqN sjbFsgbIs pB }HVC1 Cd$i=,$b #U(w UbKU{uS{UI ?] Z;V(Ra;7 !$DDRg*DW0 p^C{o4Cx %[%} &-! VqV& $B[ByvB% nl |vL#U x1) M+C|+ P{PAoFod huVXF5NVB. QII=k#%D 4by4EEL4\bQ nH0 TM^q Od A}cj# ^VTp%qe[8.

3b4%vHz

CxG[xDx

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión